Abstract
Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have